ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novartis, Pfizer and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Novartis×Pfizer×Hoffmann-La Roche×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovartisPfizerHoffmann-La Roche
studies on the registry3,9004,0732,744
open to participants now211147115
phase 3 studies under way949995
reach primary completion within a year1259275
programswith a study of their own in two years77+7 named only91+9 named only80+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovartisPfizerHoffmann-La Roche
Phase 1

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%
Phase 2

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. emicizumabapproved, new study · Nov 19 · NCT05181618
  2. nivegacetorphase 2 · Nov 19 · NCT06402838
  3. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 58 in all. A program counts in each condition its studies name most.

ConditionNovartisPfizerHoffmann-La Roche
Breast Neoplasmsall three · compare here

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Prostatic Neoplasmsall three · compare here

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopicall three · compare here

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Small Cell Lung Carcinomaall three · compare here

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Colorectal Neoplasmsall three · compare here

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Novartis in Arthritis, Rheumatoid: 5 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  4. DKB903phase 1
  5. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Rheumatoid in search

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Renal Insufficiencyall three · compare here

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Alzheimer Diseaseall three · compare here

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Neoplasmsall three · compare here

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaall three · compare here

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Hypertensionall three · compare here

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Pfizer in Hypertension: 1 program

  1. Prazosinphase 1

Their studies: Pfizer’s studies of Hypertension in search

Hoffmann-La Roche in Hypertension: 1 program

  1. zilebesiranphase 3

Their studies: Hoffmann-La Roche’s studies of Hypertension in search

Anemia, Sickle Cellall three · compare here

Novartis in Anemia, Sickle Cell: 1 program

  1. ITU512phase 2

Their studies: Novartis’s studies of Anemia, Sickle Cell in search

Pfizer in Anemia, Sickle Cell: 1 program

  1. osivelotorphase 3

Their studies: Pfizer’s studies of Anemia, Sickle Cell in search

Hoffmann-La Roche in Anemia, Sickle Cell: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Anemia, Sickle Cell in search

Ovarian Neoplasmsall three · compare here

Novartis in Ovarian Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Ovarian Neoplasms in search

Pfizer in Ovarian Neoplasms: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Ovarian Neoplasms in search

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Obesity2 of 3 · compare here–

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

COVID-192 of 3 · compare here–

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

Diabetes Mellitus, Type 22 of 3 · compare here–

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Geographic Atrophy2 of 3 · compare here

Novartis in Geographic Atrophy: 1 program

  1. FWY003phase 2

Their studies: Novartis’s studies of Geographic Atrophy in search

–

Hoffmann-La Roche in Geographic Atrophy: 4 programs

  1. RO7965032phase 2
  2. avacincaptad pegolphase 1
  3. pegcetacoplanphase 1
  4. RO7669330phase 1

Their studies: Hoffmann-La Roche’s studies of Geographic Atrophy in search

Lymphoma, B-Cell2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

Macular Degeneration2 of 3 · compare here

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

–

Hoffmann-La Roche in Macular Degeneration: 4 programs

  1. avacincaptad pegolphase 1
  2. pegcetacoplanphase 1
  3. Ranibizumabapproved, new study
  4. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Macular Degeneration in search

Non-Muscle Invasive Bladder Neoplasms2 of 3 · compare here–

Hoffmann-La Roche in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. eciskafusp alfaphase 1

Their studies: Hoffmann-La Roche’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Asthma2 of 3 · compare here–

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Colitis, Ulcerative2 of 3 · compare here–

Pfizer in Colitis, Ulcerative: 2 programs

  1. etrasimodphase 3
  2. PF-07054894phase 1

Their studies: Pfizer’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Glomerulonephritis, IGA2 of 3 · compare here

Novartis in Glomerulonephritis, IGA: 3 programs

  1. iptacopanphase 3
  2. Atrasentanphase 3
  3. zigakibartphase 3

Their studies: Novartis’s studies of Glomerulonephritis, IGA in search

–

Hoffmann-La Roche in Glomerulonephritis, IGA: 1 program

  1. sefaxersenphase 3

Their studies: Hoffmann-La Roche’s studies of Glomerulonephritis, IGA in search

Hemophilia A2 of 3 · compare here–

Pfizer in Hemophilia A: 1 program

  1. marstacimabphase 3

Their studies: Pfizer’s studies of Hemophilia A in search

Hoffmann-La Roche in Hemophilia A: 3 programs

  1. zemocimigphase 3
  2. dirloctocogene samoparvovecphase 2
  3. emicizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Hemophilia A in search

Hidradenitis Suppurativa2 of 3 · compare here

Novartis in Hidradenitis Suppurativa: 3 programs

  1. remibrutinibphase 3
  2. arumakimigphase 2
  3. secukinumabapproved, new study

Their studies: Novartis’s studies of Hidradenitis Suppurativa in search

Pfizer in Hidradenitis Suppurativa: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Hidradenitis Suppurativa in search

–
Influenza, Human2 of 3 · compare here–

Pfizer in Influenza, Human: 3 programs

  1. abrysvophase 3
  2. qIRVphase 1
  3. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Influenza, Human in search

Hoffmann-La Roche in Influenza, Human: 1 program

  1. baloxavirphase 3

Their studies: Hoffmann-La Roche’s studies of Influenza, Human in search

Lupus Nephritis2 of 3 · compare here

Novartis in Lupus Nephritis: 2 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Lupus Nephritis in search

–

Hoffmann-La Roche in Lupus Nephritis: 2 programs

  1. mosunetuzumabphase 3
  2. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Lupus Nephritis in search

Melanoma2 of 3 · compare here–

Hoffmann-La Roche in Melanoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Melanoma in search

Multiple Sclerosis, Chronic Progressive2 of 3 · compare here

Novartis in Multiple Sclerosis, Chronic Progressive: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Multiple Sclerosis, Chronic Progressive in search

–

Hoffmann-La Roche in Multiple Sclerosis, Chronic Progressive: 3 programs

  1. fenebrutinibphase 3
  2. RO7268489phase 2
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis, Chronic Progressive in search

Atherosclerosis2 of 3 · compare here

Novartis in Atherosclerosis: 2 programs

  1. pelacarsenphase 3
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Atherosclerosis in search

–

Hoffmann-La Roche in Atherosclerosis: 1 program

  1. selnoflastphase 2

Their studies: Hoffmann-La Roche’s studies of Atherosclerosis in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here

Novartis in Hemoglobinuria, Paroxysmal: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Hemoglobinuria, Paroxysmal in search

–

Hoffmann-La Roche in Hemoglobinuria, Paroxysmal: 2 programs

  1. Crovalimabphase 3
  2. pegcetacoplanphase 1

Their studies: Hoffmann-La Roche’s studies of Hemoglobinuria, Paroxysmal in search

Lymphoma, Non-Hodgkin2 of 3 · compare here

Novartis in Lymphoma, Non-Hodgkin: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Non-Hodgkin in search

–

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Neoplasm Metastasis2 of 3 · compare here–

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

Pfizer in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tilrekimigphase 3

Their studies: Pfizer’s studies of Pulmonary Disease, Chronic Obstructive in search

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

Schizophrenia2 of 3 · compare here

Novartis in Schizophrenia: 2 programs

  1. GXV-813phase 2
  2. XEP527phase 1

Their studies: Novartis’s studies of Schizophrenia in search

–

Hoffmann-La Roche in Schizophrenia: 1 program

  1. ralmitarontphase 2

Their studies: Hoffmann-La Roche’s studies of Schizophrenia in search

Stomach Neoplasms2 of 3 · compare here–

Pfizer in Stomach Neoplasms: 2 programs

  1. tivunatamigphase 3
  2. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Vitiligo2 of 3 · compare here

Novartis in Vitiligo: 2 programs

  1. GIA632phase 2
  2. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Vitiligo in search

Pfizer in Vitiligo: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Vitiligo in search

–
Atypical Hemolytic Uremic Syndrome2 of 3 · compare here

Novartis in Atypical Hemolytic Uremic Syndrome: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Atypical Hemolytic Uremic Syndrome in search

–

Hoffmann-La Roche in Atypical Hemolytic Uremic Syndrome: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Atypical Hemolytic Uremic Syndrome in search

Bronchiolitis Obliterans Syndrome2 of 3 · compare here

Novartis in Bronchiolitis Obliterans Syndrome: 1 program

  1. asciminibapproved, new study

Their studies: Novartis’s studies of Bronchiolitis Obliterans Syndrome in search

–

Hoffmann-La Roche in Bronchiolitis Obliterans Syndrome: 1 program

  1. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Bronchiolitis Obliterans Syndrome in search

Chronic Urticaria2 of 3 · compare here

Novartis in Chronic Urticaria: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Chronic Urticaria in search

Pfizer in Chronic Urticaria: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Chronic Urticaria in search

–
Coronary Artery Disease2 of 3 · compare here

Novartis in Coronary Artery Disease: 1 program

  1. YMI024phase 2

Their studies: Novartis’s studies of Coronary Artery Disease in search

–

Hoffmann-La Roche in Coronary Artery Disease: 1 program

  1. RO7763505phase 1

Their studies: Hoffmann-La Roche’s studies of Coronary Artery Disease in search

Crohn Disease2 of 3 · compare here–

Pfizer in Crohn Disease: 1 program

  1. etrasimodphase 3

Their studies: Pfizer’s studies of Crohn Disease in search

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Diabetes Mellitus2 of 3 · compare here–

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Hoffmann-La Roche in Diabetes Mellitus: 1 program

  1. enicepatidephase 3

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus in search

Endometrial Neoplasms2 of 3 · compare here–

Pfizer in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: Pfizer’s studies of Endometrial Neoplasms in search

Hoffmann-La Roche in Endometrial Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Endometrial Neoplasms in search

Heart Failure2 of 3 · compare here

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Pfizer in Heart Failure: 1 program

  1. PF-07328948phase 2

Their studies: Pfizer’s studies of Heart Failure in search

–
Huntington Disease2 of 3 · compare here

Novartis in Huntington Disease: 1 program

  1. votoplamphase 3

Their studies: Novartis’s studies of Huntington Disease in search

–

Hoffmann-La Roche in Huntington Disease: 1 program

  1. RG6496phase 1

Their studies: Hoffmann-La Roche’s studies of Huntington Disease in search

Lymphoma2 of 3 · compare here

Novartis in Lymphoma: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma in search

–

Hoffmann-La Roche in Lymphoma: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma in search

Lymphoma, Follicular2 of 3 · compare here

Novartis in Lymphoma, Follicular: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma, Follicular in search

–

Hoffmann-La Roche in Lymphoma, Follicular: 1 program

  1. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Follicular in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

Novartis in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Large B-Cell, Diffuse in search

–

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Muscular Atrophy, Spinal2 of 3 · compare here

Novartis in Muscular Atrophy, Spinal: 1 program

  1. Onasemnogene Abeparvovec-brveapproved, new study

Their studies: Novartis’s studies of Muscular Atrophy, Spinal in search

–

Hoffmann-La Roche in Muscular Atrophy, Spinal: 1 program

  1. emugrobartphase 3

Their studies: Hoffmann-La Roche’s studies of Muscular Atrophy, Spinal in search

Muscular Dystrophy, Facioscapulohumeral2 of 3 · compare here

Novartis in Muscular Dystrophy, Facioscapulohumeral: 1 program

  1. AOC 1020phase 3

Their studies: Novartis’s studies of Muscular Dystrophy, Facioscapulohumeral in search

–

Hoffmann-La Roche in Muscular Dystrophy, Facioscapulohumeral: 1 program

  1. emugrobartphase 3

Their studies: Hoffmann-La Roche’s studies of Muscular Dystrophy, Facioscapulohumeral in search

Nasal Polyps2 of 3 · compare here–

Pfizer in Nasal Polyps: 1 program

  1. rimegepantapproved, new study

Their studies: Pfizer’s studies of Nasal Polyps in search

Hoffmann-La Roche in Nasal Polyps: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Nasal Polyps in search

Pancreatic Neoplasms2 of 3 · compare here

Novartis in Pancreatic Neoplasms: 1 program

  1. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Pancreatic Neoplasms in search

–

Hoffmann-La Roche in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Pancreatic Neoplasms in search

Psoriasis2 of 3 · compare here

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Pfizer in Psoriasis: 1 program

  1. abrocitinibphase 3

Their studies: Pfizer’s studies of Psoriasis in search

–
Pulmonary Arterial Hypertension2 of 3 · compare here

Novartis in Pulmonary Arterial Hypertension: 1 program

  1. LTP001phase 2

Their studies: Novartis’s studies of Pulmonary Arterial Hypertension in search

Pfizer in Pulmonary Arterial Hypertension: 1 program

  1. PF-07868489phase 2

Their studies: Pfizer’s studies of Pulmonary Arterial Hypertension in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Novartis in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Squamous Cell Carcinoma of Head and Neck in search

Pfizer in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpha V Beta 8 Antagonist PF-06940434phase 1

Their studies: Pfizer’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Novartis 56 of 77 · Pfizer 67 of 91 · Hoffmann-La Roche 40 of 80 programs (52 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7, Pfizer: 9, Hoffmann-La Roche: 25).